OBJECTIVES: Treatment for CRPC has evolved rapidly with  new drug approvals.  However, few studies have evaluated recent treatment patterns. Our objective was to describe treatment sequences after CRPC diagnosis in EU-5 countries (UK, Germany, Spain, Italy, France).  METHODS: This study used IMS Oncology Analyzer, a proprietary database of patient chart abstractions, collected through a quarterly physician panel survey. The data includes the history of the patient’s cancer from diagnosis and treatment choices.. The most recent panels of data (July 2011 - June 2012) were used to identify patients with physician-defined CRPC and to describe treatments initiated after CRPC diagnosis. RESULTS: Of 4479 prostate cancer patients, 624 patients had CRPC defined by the physicians (32% UK, 21% Germany, 18% Spain, 15% Italy, 14% France). A total of 76.4% of patients were >65y.  A total of 57.7% were diagnosed with CRPC within the past year; 90.1% had metastases, mostly bone (80.4%).  After CRPC diagnosis, 50.5% of patients (n=280) had docetaxel-alone specified as first therapy, of which 34.6% had a second treatment specified [52.5% chemotherapy, 40.2% androgen deprivation therapy (ADT) only]. Median time on first docetaxel therapy was 181 days; median number of cycles was five.  A total of 24.5% of CRPC patients (n=136) continued with only single-agent ADT as first therapy, of which 53.7% had a second treatment specified [56.2% chemotherapy; 39.7% ADT; 2.7% combined chemo-ADT].  A total of 16.0% of CRPC patients had multiple-agent ADT specified as first therapy after CRPC diagnosis, and 3.4% had combined chemo-ADT.  Of the 502 CRPC patients with bone metastases, 34.1% received zoledronic acid and 16.5% radiotherapy after their diagnosis of CRPC. CONCLUSIONS: Docetaxel was the most common first treatment after CRPC diagnosis, followed by continued ADT. Few physicians specified combined chemotherapy with ADT. Low rates of initiation of zoledronic acid in patients with bone metastases warrants study on alternative timing and choices.